RCC Risk & Follow-Up Planner
Choose EAU 2026 or AUA/NCCN + Leibovich below, then estimate post-nephrectomy risk and view a risk-adapted surveillance schedule for renal cell carcinoma (RCC).
Produced by Dr. Mohit Sharma, UROWALA
Clear cell RCC — progression-free survival score
Papillary RCC — simplified risk grouping
Papillary RCC risk grouping uses fewer, broader pathologic strata than the clear-cell model. This tool applies a simplified stage/size/node approximation of the published groupings — confirm exact staging with the original 2018 Leibovich publication or MDCalc before clinical use.
Chromophobe RCC — risk grouping
Suggested post-nephrectomy surveillance schedule
| Surveillance item | Low risk | Intermediate risk | High risk |
|---|---|---|---|
| History, exam & labs (BMP, LFTs) | 6 mo, then annually to yr 5 | Every 6 mo through yr 3, then annually to yr 5 | Every 3–6 mo through yr 3, then every 6 mo to yr 5 |
| Chest imaging (CT preferred) | Annually, yrs 1–3 | Every 6 mo, yrs 1–3; annually yrs 4–5 | Every 3–6 mo, yrs 1–3; every 6 mo yrs 4–5 |
| Abdominal imaging (CT/MRI, contralateral kidney + fossa) | Baseline 3–12 mo; then only if indicated | Every 6 mo, yrs 1–3; annually yrs 4–5 | Every 3–6 mo, yrs 1–3; every 6–12 mo yrs 4–5 |
| Beyond year 5 | As clinically indicated | Consider annual imaging; late recurrences reported | Continue annual surveillance; discuss trial/adjuvant options |
Schedule reflects commonly used risk-stratified surveillance frameworks (AUA/NCCN-style) for surgically treated, non-metastatic RCC. Individualize based on comorbidities, renal function, contrast tolerance, and shared decision-making.
EAU 2026 risk & follow-up
EAU 20262003 Leibovich score — the model the EAU panel recommends (weak) for risk-of-recurrence stratification of localised/locally advanced ccRCC, distinct from the 9‑variable 2018 model used above.
Applies to papillary, chromophobe and other non-clear-cell histologies, per the pT/pN/grade criteria in EAU Table 9.1. For papillary RCC specifically, the panel separately endorses the VENUSS score (next tab) as a validated alternative.
VENUSS = Venous involvement, Necrosis, Size, Stage, Sarcomatoid differentiation — the EAU panel's recommended (weak) model specifically for papillary RCC risk-of-recurrence stratification.
EAU 2026 proposed follow-up schedule (Table 9.1)
| Risk | 3mo | 6mo | 12mo | 18mo | 24mo | 30mo | 36mo | >3yr | >5yr |
|---|---|---|---|---|---|---|---|---|---|
| Low | – | CT | – | CT | – | CT | – | CT / 2yr | –* |
| Intermediate | – | CT | CT | – | CT | – | CT | CT / yr | CT / 2yr** |
| High | CT | CT | CT | CT | CT | – | CT | CT / yr | CT / 2yr |
- CT = chest + abdomen CT at each listed time point after surgery; abdominal MRI may substitute for abdominal CT.
- *Low risk, >3 years, and **intermediate risk, >5 years: the panel suggests counselling the patient on stopping oncological follow-up imaging, based on comorbidities, age, life expectancy and patient wishes.
- Intensify follow-up after nephron-sparing surgery with a positive surgical margin (weak recommendation).
- Consider curtailing follow-up once the risk of dying from other causes is roughly double the risk of RCC recurrence (weak recommendation).
- Functional follow-up (renal function, cardiovascular risk) continues per clinical need regardless of oncological follow-up duration.
- Routine PET-CT and bone scintigraphy are not recommended; targeted imaging (e.g. brain MRI) only for organ-specific symptoms.
- The panel suggests offering psychological evaluation to all patients diagnosed with RCC, and nephrology referral for pre-existing/treatment-induced CKD or risk factors for renal function deterioration.
Source: EAU Guidelines on Renal Cell Carcinoma 2026 — Chapter 6 (Prognostic Factors) and Chapter 9 (Follow-up in RCC), uroweb.org/guidelines/renal-cell-carcinoma. Reproduced here for education; verify against the current full-text guideline before clinical use.
EAU 2026 section above: uses the 2003 Leibovich score, the EAU Table 9.1 pT/pN/grade criteria for non-ccRCC, the VENUSS score for papillary RCC, and the EAU Table 9.1 follow-up schedule, as published in the EAU Guidelines on Renal Cell Carcinoma 2026 (uroweb.org/guidelines/renal-cell-carcinoma). The two sections are intentionally separate models and may not agree on a given patient's risk tier.
Neither section is a validated substitute for the original publications, MDCalc, or the current full-text EAU guideline, and neither should replace clinical judgment, multidisciplinary input, or patient-specific decision-making.